Infection with Kaposi's sarcoma-associated herpesvirus (KSHV) and human immunodeficiency virus (HIV) in relation to the risk and clinical presentation of Kaposi's sarcoma in Uganda

R Newton; J Ziegler; D Bourboulia; D Casabonne; V Beral; E Mbidde; L Carpenter; D M Parkin; H Wabinga; S Mbulaiteye; H Jaffe; R Weiss; C Boshoff

doi:10.1038/sj.bjc.6601113

Infection with Kaposi's sarcoma-associated herpesvirus (KSHV) and human immunodeficiency virus (HIV) in relation to the risk and clinical presentation of Kaposi's sarcoma in Uganda

Br J Cancer. 2003 Aug 4;89(3):502-4. doi: 10.1038/sj.bjc.6601113.

Authors

R Newton¹, J Ziegler, D Bourboulia, D Casabonne, V Beral, E Mbidde, L Carpenter, D M Parkin, H Wabinga, S Mbulaiteye, H Jaffe, R Weiss, C Boshoff

Affiliation

¹ Cancer Research UK, Epidemiology Unit, Gibson Building, Radcliffe Infirmary, Oxford OX2 6HE, UK.

Abstract

A case-control study from Uganda found that the risk of Kaposi's sarcoma increased with increasing titre of antibodies against Kaposi's sarcoma-associated herpesvirus (KSHV) latent nuclear antigens, independently of HIV infection. Clinically, widespread Kaposi's sarcoma was more frequent among patients with HIV infection than in those without, but was not related to anti-KSHV antibody titres.

Publication types

Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.

MeSH terms

Adolescent
Adult
Antibodies, Viral / analysis
Case-Control Studies
Female
HIV Infections / complications*
Herpesvirus 8, Human / pathogenicity*
Humans
Male
Risk Factors
Sarcoma, Kaposi / pathology*
Sarcoma, Kaposi / virology*
Seroepidemiologic Studies
Severity of Illness Index
Uganda / epidemiology

Substances

Antibodies, Viral